Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

NCT04288765 is registered in ClinicalTrials.gov with Grupo Cooperativo de Hemopatías Malignas as lead sponsor.

NCT NCT04288765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04288765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma
Lead sponsor
Grupo Cooperativo de Hemopatías Malignas
Phase
Phase 3
Overall status
Withdrawn
Start date
March 1, 2020
Completion date
February 28, 2025
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma